Aug 11, 2022

Starpharma announces new research agreement for DEP drug delivery platform

"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune. Read the full article here.

 This contains certain forward-looking statements.